(Q34000631)

30 July 2017

1 reference

title

Advances in strategies to improve drug delivery to brain tumors (English)

1 reference

30 July 2017

1 reference

1 reference

Herbert B Newton

1

1 reference

30 July 2017

publication date

1 October 2006

1 reference

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

30 July 2017

published in

1 reference

30 July 2017

volume

6

1 reference

30 July 2017

issue

10

1 reference

30 July 2017

page(s)

1495-1509

1 reference

Current epidemiological trends and surveillance issues in brain tumors

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1495

Epidemiology of primary brain tumors: current concepts and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1495

Cancer surveillance series [corrected]: brain and other central nervous system cancers: recent trends in incidence and mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1495

Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1495

Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1495

Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 1: growth factor and Ras signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1495

Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 2: PI3K/Akt/PTEN, mTOR, SHH/PTCH and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1495

Molecular neuro-oncology and the development of targeted therapeutic strategies for brain tumors. Part 5: apoptosis and cell cycle

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1495

Therapeutic advances in the treatment of glioblastoma: rationale and potential role of targeted agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1495

Development of the blood-brain barrier: a historical point of view

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1495

Blood-brain barrier biology and methodology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1495

Molecular biology of the blood-brain barrier

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1495

Blood-brain barrier genomics, proteomics, and new transporter discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1495

Astrocyte-endothelial interactions at the blood-brain barrier

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1495

Molecular physiology and pathophysiology of tight junctions in the blood-brain barrier

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1495

Tight junctions of the blood-brain barrier: development, composition and regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1495

Occludin: structure, function and regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1495

Claudins and epithelial paracellular transport

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1495

The JAM family of junctional adhesion molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1495

The role of drug transporters at the blood-brain barrier

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1495

A family of drug transporters: the multidrug resistance-associated proteins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1495

Microvessel organization and structure in experimental brain tumors: microvessel populations with distinctive structural and functional properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1495

Drug entry into the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1495

Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1495

Transporting therapeutics across the blood-brain barrier

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1495

Outwitting the blood-brain barrier for therapeutic purposes: osmotic opening and other means

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1495

Brain drug targeting and gene technologies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1495

Drug and gene targeting to the brain with molecular Trojan horses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1495

Targeting neurotherapeutic agents through the blood-brain barrier

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1495

Brain endothelial cells as pharmacological targets in brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1495

Cell biology of the neurovascular unit: implications for drug delivery across the blood-brain barrier

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1495

Development of neuropeptide drugs that cross the blood-brain barrier

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1495

Small molecular drug transfer across the blood-brain barrier via carrier-mediated transport systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1495

Hydrogen bonding potential as a determinant of the in vitro and in situ blood-brain barrier permeability of peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1495

Glycation increases the permeability of proteins across the blood-nerve and blood-brain barriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1495

Pharmacokinetic and biodistribution properties of poly(ethylene glycol)–protein conjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1495

Effect of pegylation on pharmaceuticals

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1495

Combined use of carboxyl-directed protein pegylation and vector-mediated blood-brain barrier drug delivery system optimizes brain uptake of brain-derived neurotrophic factor following intravenous administration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1495

Pegylation: engineering improved biopharmaceuticals for oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1495

Retention of biologic activity of human epidermal growth factor following conjugation to a blood-brain barrier drug delivery vector via an extended poly(ethylene glycol) linker

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1495

Facilitation of drug entry into the CNS via transient permeation of blood brain barrier: laboratory and preliminary clinical evidence from bradykinin receptor agonist, Cereport.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1495

Nanoparticulate systems for brain delivery of drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1495

Nanoparticle technology for drug delivery across the blood-brain barrier

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1495

Drug transport to brain with targeted nanoparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1495

Neuroscience nanotechnology: progress, opportunities and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1495

A review of nanocarrier-based CNS delivery systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1495

Synthesis of pegylated immunonanoparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1495

Toxicological studies of doxorubicin bound to polysorbate 80-coated poly(butyl cyanoacrylate) nanoparticles in healthy rats and rats with intracranial glioblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1495

Chemotherapy of glioblastoma in rats using doxorubicin-loaded nanoparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1495

Paclitaxel nanoparticles for the potential treatment of brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1495

Entrapment of small molecules and nucleic acid-based drugs in liposomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1495

Drug transport to brain with targeted liposomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1495

The formulation of lipid-based nanotechnologies for the delivery of fixed dose anticancer drug combinations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1495

Brain drug delivery of small molecules using immunoliposomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1495

Antisense gene therapy of brain cancer with an artificial virus gene delivery system

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1495

Advantages of liposomal delivery systems for anthracyclines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1495

Pegylated liposomal doxorubicin: proof of principle using preclinical animal models and pharmacokinetic studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1495

Liposome-mediated therapy of intracranial brain tumors in a rat model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1495

Distribution of liposomes into brain and rat brain tumor models by convection-enhanced delivery monitored with magnetic resonance imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1495

High intratumoural accumulation of stealth liposomal doxorubicin (Caelyx) in glioblastomas and in metastatic brain tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1495

Long-term stabilization in patients with malignant glioma after treatment with liposomal doxorubicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1495

Pegylated liposomal doxorubicin-efficacy in patients with recurrent high-grade glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1495

Phase 2 study of temozolomide and Caelyx in patients with recurrent glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1495

Convection-enhanced delivery of macromolecules in the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1495

Extensive distribution of liposomes in rodent brains and brain tumors following convection-enhanced delivery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1495

Convection-enhanced delivery in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1495

Convection-enhanced delivery of targeted toxins for malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1495

Convection-enhanced delivery of immunotoxins and radioisotopes for treatment of malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1495

Local delivery of antineoplastic agents by controlled-release polymers for the treatment of malignant brain tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1495

Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1495

Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: a randomized double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1495

Controlled-release microchips

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1495

Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1495

(131)I-chTNT-1/B mAb: tumour necrosis therapy for malignant astrocytic glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1495

Immunotoxins and central nervous system neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1495

Local treatment of brain tumors with targeted chimera cytotoxic proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1495

DAB389EGF fusion protein therapy of refractory glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1495

Recombinant toxins as novel therapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1495

Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1495

Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM107) for therapy of malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1495

Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malig

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1495

Targeted delivery across the blood-brain barrier

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1495

Anti-transferrin receptor antibody and antibody-drug conjugates cross the blood-brain barrier

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1495

Transport across the primate blood-brain barrier of a genetically engineered chimeric monoclonal antibody to the human insulin receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1495

Blood-brain barrier drug targeting: the future of brain drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1495

Improved bioavailability to the brain of glycosylated Met-enkephalin analogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1495

The controlled intravenous delivery of drugs using PEG-coated sterically stabilized nanospheres.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.10.1495

10.1586/14737175.6.10.1495

21 January 2018

Identifiers

DOI

1 reference

30 July 2017

1 reference